Eyeing a market of millions of chronic kidney disease patients — and with a favorable reimbursement decision in China that took effect Jan. 1— the company is readying a major sales and education effort aimed at hospitals and doctors.
SAN FRANCISCO, May 08, 2020 -- FibroGen, Inc. (NASDAQ: FGEN) will participate in the Bank of America Securities 2020 Health Care Conference that is being held virtually on May.
Company hits 52-week high of $12.25 Continue reading...
SAN FRANCISCO, April 24, 2020 -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2020 financial results on Thursday, May 7, 2020. FibroGen will also conduct a.
Anyone researching FibroGen, Inc. (NASDAQ:FGEN) might want to consider the historical volatility of the share price...
Company also exceeds offering target Continue reading...
SAN FRANCISCO, May 27, 2020 -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
FibroGen, Inc. (NASDAQ:FGEN) just released its latest first-quarter report and things are not looking great. Statutory...
Q1 2020 FibroGen Inc Earnings Call
Q4 2019 FibroGen Inc Earnings Call
FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Last week, you might have seen that FibroGen, Inc. (NASDAQ:FGEN) released its annual result to the market. The early...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced the marketing authorization application (MAA) for roxadustat for the treatment of anemia in adult patients with chronic kidney disease (CKD) has been accepted by the European Medicines Agency (EMA) for regulatory review.
Ladies and gentlemen, thank you for standing by, and welcome to the FibroGen First Quarter 2020 Financial Results. Thank you for joining us on today's call to discuss FibroGen's results for the first quarter of 2020. Today's call will be led by Enrique Conterno, our Chief Executive Officer.
- Roxadustat U.S. NDA review and E.U. MAA filing on track - Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time SAN FRANCISCO, May 07, 2020 -- FibroGen,.
FibroGen, Inc. (FGEN) today announced that the United Kingdom’s High Court of Justice has held certain patents1 relating to methods of using hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) to be invalid. This decision does not affect the validity of these patents across the rest of Europe. While FibroGen is disappointed with the court’s decision, this UK ruling does not affect development or commercialization timelines for roxadustat, FibroGen’s HIF-PHI for treatment of anemia in chronic kidney disease, including in the UK or elsewhere in Europe.
TOKYO and SAN FRANCISCO, May 21, 2020 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique.
FibroGen (FGEN) delivered earnings and revenue surprises of -80.65% and -74.01%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.